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THE PROTEOLYTIC CLEAVAGE OF SEMA3F MAY BE MEDIATED BY 
NON-FURIN PROPROTEIN CONVERTASES 
ERIK LI 
ABSTRACT 
 Class III Semaphorins (SEMA3) comprise a family of chemokines that 
have been implicated as negative regulators of axonal guidance, angiogenesis and 
tumor progression. It has been demonstrated previously that one SEMA3, 
SEMA3F, may have therapeutic potential in the treatment of cancer.  When 
transfected with SEMA3F, the highly metastatic human melanoma cell line 
A375SM was found to exhibit a highly-encapsulated, avascular phenotype with 
limited metastasis. Members of SEMA3 are regulated on many levels, including 
proteolytic processing. SEMA3F, like other SEMA3, is expressed as a 100 kD 
proprotein that is seen to be processed in vitro and in vivo to 95 and 65 kD 
isoforms. This has been largely attributed to furin-like endoproteases on the basis 
of furin inhibition studies. However, currently available small chemical or 
peptide inhibitors against the family of subtilisin/kexin-type proprotein 
convertases (PCSK), to which furin belongs, do not have good selectivity between 
PCSKs. Cleavage of SEMA3 to 65 kD have been shown to have differing effects. 
SEMA3A loses its ability to repel sympathetic ganglia and SEMA3E reverses its 
phenotype from chemorepulsant to chemoattractant for developing vasculature 
following cleavage. In order to further develop therapeutic strategies based on 
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SEMA3F, it is therefore critical to better understand the proteolytic regulation of 
this molecule. In this study, it is shown that digest of purified SEMA3F with 
purified recombinant human furin does not result in proteolytic cleavage and 
suggested that the cleavage of SEMA3F to a 65 kD isoform may be mediated by 
other members of the PCSK family. 
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INTRODUCTION 
Class III Semaphorins (SEMA3) are a large class of secreted signaling molecules 
first described as chemorepulsive and inhibitory modulators of axonal guidance. 
An increasing number of semaphorins have been identified and they have been 
implicated not only in the nervous system but also in vascular and tumor biology. 
Structurally, semaphorins are related by an N-terminal conserved ~500 
amino acid sema domain. The SEMA3, which encompass the seven secreted 
members of the semaphorin family in vertebrate animals (SEMA3A-G), 
additionally share homology over C-terminally located immunoglobulin-like and 
basic domains (“Unified Nomenclature,” 1999). SEMA3 mediate their effects by 
binding to a holoreceptor complex comprised of neuropilins (NRP) and plexins. 
NRP are able to recognize and bind the sema domain of SEMA3, but because 
their cytoplasmic domains are relatively short, it is believed that they have 
limited signal transduction ability. NRP therefore complex with plexins, which 
contain a cytoplasmic domain with GTPase-activating activity (Neufeld & Kessler, 
2008). The signaling pathway of SEMA3F has been shown to involve Abelson 2 
tyrosine kinase in the inactivation of the RhoA pathway, downstream activation 
of cofilin and depolymerization of f-actin (Figure 1, Shimizu et al., 2008). RhoA-
mediated cytoskeletal reorganization and collapse has been implicated in the 
signaling pathways of many SEMA3 and is thought to contribute to their ability 
to inhibit angiogenesis, neurogenesis, cell migration, adhesion and survival 
(Bielenberg & Klagsbrun, 2007). 
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Figure 1: SEMA3F binding to neuropilin initiates an enzymatic 
cascade resulting in cytoskeletal reorganization. Binding of SEMA3F 
to NRP2 induces Plexin A1 to recruit Abelson 2 tyrosine kinase, which 
phosphorylates and activates p190 RhoGAP. This, in turn, leads to the 
deactivation cascade of RhoA, Rho kinase and LIM kinase. This activates 
cofilin and depolymerizes F-actin. Reproduced from Shimizu et al. (2008). 
NRP are also able to bind vascular endothelial growth factor (VEGF) and 
complex with VEGF receptors (VEGFR) to potentiate proangiogenic effects. NRP 
are structurally organized into a1/a2, b1/b2, c, transmembrane and short 
cytoplasmic domains. VEGF is thought to bind the NRP b1/b2 domain, whereas 
the sema domain of SEMA3 is thought to bind the a1/a2 domain. The C-terminal 
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end of SEMA3 may also compete with VEGF for binding the b1/b2 pocket. 
Functionally, SEMA3A has been shown to  compete VEGF-induced endothelial 
cell motility (Miao et al., 1999). However, some structural studies have suggested 
that SEMA3 and VEGF may not directly compete for binding in the b1/b2 domain 
(Appleton et al., 2007). 
The c domain of NRP is thought to have a role in dimerization, which is 
required for NRP functionality. Prematurely truncated transcripts of NRP are 
translated to soluble isoforms of NRP that contain only a1/a2 domains and b1/b2 
domains (Bielenberg et al., 2006). These soluble NRP act to inhibit NRP function 
by competing with membrane-bound NRP for SEMA3 and VEGF. 
The different isoforms of NRP, SEMA3 and plexin differ in tissue 
expression and binding specificity. During murine development NRP1 is 
predominantly found in the arterial vasculature and NRP2 in the venous and 
lymphatic vasculatures (Bielenberg & Klagsbrun, 2007). SEMA3A signals 
through NRP1 and SEMA3F/G signal through NRP2, while SEMA3B-D are able 
to signal through both. SEMA3E is an exception and binds directly through 
Plexin D1 (Figure 2). The size of the semaphorin and VEGF families as well as 
their differential affinities for NRP1 and NRP2 suggest that members of each 
family may have non-overlapping functionality, enabling fine-tuned control of 
vascular development and other SEMA3-mediated processes (Gaur et al., 2009). 
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Figure 2: SEMA3, NRP and plexins show specificity in their 
interactions. Differences in ligand-binding affinity and tissue expression 
suggest that SEMA3, NRP and plexins each occupy specific biological 
niches. Reproduced from Gaur et al. (2009). 
In the tumor context, many researchers have posited the idea of an 
“angiogenic switch”, which is a crucial step in tumor progression to provide 
sufficient nourishment for growth and a metastatic route (Varshavsky et al., 
2008). The ability of NRP to bind both SEMA3 and VEGF suggests that it may 
play an important role in determining angiogenic balance. Many therapeutic 
approaches have therefore targeted NRP in order to prevent its proangiogenic 
effects or enhance its antiangiogenic effects. It has been shown previously that 
SEMA3F may have therapeutic potential in the treatment of cancer (Bielenberg et 
al., 2004). SEMA3F and SEMA3B genes are located in chromosomal region 
3p21.3, which is commonly deleted in small cell lung cancer (Xiang et al., 2002). 
Progressive loss of SEMA3F expression also appears to be associated with tumor 
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progression and development of a metastatic phenotype. In our 2004 study, 
transfection of the highly metastatic human melanoma cell line A375SM with 
SEMA3F was shown to induce a highly encapsulated, avascular phenotype and 
almost completely prevented the formation of lung and lymph node metastasis 
when these cells were injected into nude mice (Bielenberg et al., 2004). 
SEMA3 have also been shown to be regulated by proteolytic processing. 
They are expressed as 100 kD proproteins and subsequently processed to 95 and 
65 kD isoforms. The functional consequence of these proteolytic processing 
events seems variable within the SEMA3 family. For SEMA3A, it has been shown 
that cleavage to the p65 form prevents dimerization by removing a downstream 
cysteine residue, resulting in the functional loss of repelling ability (Figure 3, 
Adams et al., 1997; Klostermann et al., 1998). SEMA3B is similarly inactivated by 
cleavage to the p65 form and wild-type SEMA3B demonstrates limited ability to 
retard the growth and metastasis of most cancers since it is particularly 
susceptible to cleavage in the tumor environment, which typically upregulate 
proteolytic pathways (Varshavsky et al., 2008). In contrast, p95 SEMA3E has a 
repulsive phenotype but has been shown to acquire a prometastatic phenotype 
upon cleavage to the p65 isoform (Christensen et al., 2005). Expanding our 
understanding of the role of proteolytic processing in the regulation of SEMA3F 
is therefore critical to the therapeutic application of SEMA3F. 
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Figure 3: Two putative cleavage sites (PCS) are conserved across the 
SEMA3 family. These two cleavage sites process the SEMA3 family 
members to 95 and 65 kD isoforms. Aligned sequences from members of 
the SEMA3 family, including mouse orthologs Sema3A, Sema3B, 
Sema3C and Sema3F, chick SEMA3A ortholog collapsin-1 (C1) and 
chick SEMA3D ortholog collapsin-2 (C2) are shown above. From left to 
right, shaded regions in the schematic above correspond to the signal 
sequence, sema domain and Ig domain. Cleavage at the p95 site of 
Sema3A has been shown to be required for Sema3A to acquire an 
inhibitory phenotype. Asterisk represents the location of the conserved 
cysteine residue necessary for the formation of dimeric SEMA3, located at 
residue 723 in Sema3A. Cleavage of Sema3A at the p65 site therefore 
prevents dimerization of Sema3A, resulting in a functional loss of 
repulsive and collapsing phenotypes. Adapted from Guo et al. (2013) and 
Klostermann et al. (1998). 
Furin or furin-like endoproteases have been implicated in this cleavage on 
the basis of furin inhibition and cleavage site mutation studies (Adams et al., 
1997; Christensen et al., 2005; Guo et al., 2013; Parker et al., 2010; Varshavsky et 
al., 2008). Furin is a member of the subtilisin/kexin-type proprotein convertase 
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(PCSK) family of serine endoproteases, which cleave C-terminally to the R-X-
(R/K/X)-R↓ motif (Remacle et al., 2008). At least two such motifs have been 
found to be conserved across the SEMA3 family, one located centrally and the 
other located C-terminally(Adams et al., 1997). Furin has been identified in 
almost all examined mammalian cell lines and plays a major role in the 
proteolytic activation of a wide range of enzymes and signaling molecules. Small 
chemical and peptide inhibitors of PCSKs suffer from poor selectivity between the 
PCSKs and limit the ability of currently published studies to identify which PCSK 
is specifically responsible for SEMA3 cleavage (Zhong et al., 1999). 
The Vander Kooi laboratory has recently published two papers focusing on 
the interaction of SEMA3F and VEGF, two competitive ligands for the NRP2 
receptor. In their studies, they used recombinant protein and small peptide 
synthesis of the C-terminal portion of SEMA3F to demonstrate that SEMA3F is 
unable to competitively inhibit VEGF binding unless it exposes a C-terminal 
arginine, as it would following furin cleavage (Parker et al., 2010). Mutational 
analysis of a small peptide corresponding to the last 40 amino acids of p95 
SEMA3F demonstrated that point mutation of a conserved cysteine residue could 
disrupt dimer formation, resulting in a monomeric peptide with 40-fold decrease 
in inhibition as compared to the dimeric peptide (Figure 4, Guo et al., 2013). 
8 
 
Figure 4: Mutation of a cysteine residue within a peptide construct 
corresponding to the SEMA3F C-terminal construct results in a 
monomeric peptide with reduced inhibition. A, A construct 
corresponding to the C-terminal residues of mouse Sema3F following a 
p95 cleavage event was constructed (C-furSema). Mutation of the internal 
cysteine residue of C-furSema to serine prevented the construct from 
forming dimers. B, The ability of monomeric C-furSema to compete with 
VEGF for the binding of mouse Nrp1 was significantly reduced as 
compared to that of dimeric C-furSema. Adapted from Guo et al. (2013). 
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SPECIFIC AIMS 
The overarching aim of this study is to elucidate the role of specific PCSKs in the 
cleavage and regulation of SEMA3F, which the Bielenberg laboratory has 
previously investigated as a cancer therapeutic to prevent metastasis and retard 
growth. Proteolytic processing has been shown to be an important regulator of 
many members in the SEMA3 family, such as SEMA3A, SEMA3B and SEMA3E. 
Recent studies have suggested that C-terminal cleavage of SEMA3F to its 95 kD 
isoform by furin is important for SEMA3F to effectively compete with VEGF for 
NRP2 binding, but relatively little has been published on the 65 kD isoform 
regarding cleavage and resultant activity. 
This study will pursue three approaches to investigate the p65 cleavage of 
SEMA3F. These encompass pure protein digests, transfection of PCSK-deficient 
and wild-type cell lines and siRNA knockdown of specific endoproteases. In 
pursuing the first, purified SEMA3F will be incubated with recombinant human 
furin (rhFurin), varying both digest duration and SEMA3F:rhFurin ratio. 
Secondly, this study will examine the presence of specific SEMA3F isoforms in 
the conditioned media of furin-deficient and furin-complemented CHO-K1 
strains RPE.40 and 40.fur following transfection with SEMA3F. Finally, the 
competence of human melanoma A375SM cells previously transfected with 
SEMA3F for additional transfection with siRNA will be determined to assess 
their suitability for siRNA studies. 
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METHODS 
Cell culture 
Minimum Essential Medium (MEM), Dulbecco's Modified Eagle Medium 
(DMEM), 1:1 DMEM/Ham's F12 Medium (DMEM/F12), 0.05% Trypsin/EDTA 
and 100x Penicillin-Streptomycin-Glutamine (GPS) were purchased from Gibco 
Life Technologies. Dimethyl sulfoxide was purchased from Sigma-Aldrich. When 
complete medium is specified, medium was supplemented with 10% Fetal Bovine 
Serum (FBS, Denville Scientific) and 1x GPS. Human Embryonic Kidney (HEK) 
cells transformed with SV40 large T antigen (HEK293FT, Gibco Life 
Technologies) were cultured with complete DMEM supplemented with 
4.5 mg/ml D-glucose. 500 μg/ml Geneticin (Gibco) was used to maintain SV40 
transfection. 
A375SM cells were previously obtained from the Fidler laboratory (MD 
Anderson Cancer Center, Houston, TX) and originally derived by orthotopically 
cycling the human melanoma cell line A375P in nude mice and isolating 
metastatic cancer cells (Li et al., 1989). Creation of a pSecTag2A vector encoding 
SEMA3F (Ascension #HSU38276) was previously described (Bielenberg et al., 
2008). This vector replaced the SEMA3F signal sequence with the IgΚ leader 
sequence and C-terminally linked c-myc and His tags to SEMA3F. pSecTag2A 
also conferred transfected cells with resistance to zeocin. A375SM cells were 
subsequently transfected with this vector and stable transfectants were selected 
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and maintained using 500 μg/ml zeocin (Gibco Life Technologies). This paper 
will refer to this stably transfected A375SM cell line as SM/SEMA3F (Bielenberg 
et al., 2004). 
RPE.40 cells are a furin-deficient CHO-K1-derived line of cells first 
identified for their resistance to Pseudomonas endotoxin due to an inability to 
proteolytically process and mature the pathological endotoxin. RPE.40 cells and 
RPE.40 cells stably transfected with mouse furin (40.fur cells) were kindly 
provided by Joseph Sucic (Moehring et al., 1993). Both cell types were cultured in 
complete DMEM/F12 media. 
All cells were cultured at 37 ºC in a humidified incubator. A375SM and 
SM/SEMA3F cells were cultured with 10% CO2. HEK293FT, RPE.40 and 40.fur 
cells were cultured with 5% CO2. 10 cm cell culture plates were seeded with 
106 cells and maintained at 30–80% confluence. 
SEMA3F Purification 
C-terminally c-myc/His-tagged SEMA3F was purified as previously described 
(Bielenberg et al., 2008). Briefly, HEK293FT were transiently transfected with 
the pSecTag2A SEMA3F plasmid described above and the media was replaced 
with serum-free CD293 medium (Invitrogen). After 48 hours, conditioned media 
were collected, centrifuged 15 min at 16,900 g and filtered through a 0.22 μm 
polyvinylidene fluoride (PVDF) membrane. The C-terminal His tag allows 
SEMA3F to be purified by nickel affinity. A HiTrap high-performance chelating 
column (GE Healthcare Amersham Biosciences) was prepared with NiSO4 and 
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equilibrated with phosphate-buffered saline (PBS). The nickel column was 
connected to a fast protein liquid chromatography (FPLC) machine and SEMA3F 
was sequestered in the column. SEMA3F was eluted from the column using a 
high-salt buffer and desalted with a PD-10 gel filtration column (GE Healthcare). 
The expected yield from fifteen 15-cm tissue culture plates was about 5 mg. 
Purified SEMA3F was stored at -80 ℃. 
Production of anti-SEMA3F antibody in rabbit 
An antibody against the sema domain of SEMA3F was raised in rabbit and 
purified to a concentration of 0.781 mg/ml. Rabbit anti-SEMA3F antibody was 
produced previously by Akio Shimizu. 
Lower limit of SEMA3F detection by Western blot 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
The molecular weight of purified SEMA3F was confirmed by Sodium Dodecyl 
Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western blot. 
Protogel (30% acrylamide, 0.8% bis-acrylamide), 4x Resolving Buffer and 4x 
Stacking Buffer were purchased from National Diagnostics. 10x Running Buffer 
was purchased from Boston Bioproducts. Tetramethylethylenediamine was 
purchased from JT Baker and ammonium persulfate was purchased from Sigma-
Aldrich. 
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10-well polyacrylamide gels were handcast at 1.5 mm thick using a 
Bio-Rad Mini-PROTEAN Tetra Cell system. The resolving layer (pH 8.8) was cast 
at 7.5 wt% polyacrylamide and the stacking layer (pH 6.8) at 3.9 wt%. 
In order to determine the lower limit of detection for SEMA3F, differing 
quantities of SEMA3F were loaded into each well. 100, 200, 400 and 600 ng 
samples of SEMA3F were prepared in duplicate. Samples were prepared under 
reducing conditions using reducing sample buffer (Boston Bioproducts) and 
diluted to 36 μl loading volume using double-distilled water (ddH2O). 
SDS-PAGE gels were run at 90 V for 2 h until the Kaleidoscope Prestained 
Standards (Bio-Rad) were clearly separated. All subsequent SDS-PAGE gels were 
run using these parameters unless otherwise specified. 
Transfer of SDS-PAGE to nitrocellulose membrane by Western blot 
Gels were transferred to nitrocellulose membranes before probing with 
antibodies. 10x Transfer Buffer and 10x tris-buffered saline (TBS) was purchased 
from Boston Bioproducts. 
0.45 μm nitrocellulose membrane (Bio-Rad) and two pieces of 3MM 
chromatography filter paper (Whatman) were cut to 6×9 cm. Nitrocellulose 
membrane, filter paper and two sponges were immersed in transfer buffer and 
polyacrylamide gels were removed from the SDS-PAGE apparatus. Nitrocellulose 
membrane was placed against the gel and then both were sandwiched between 
filter paper and sponges. Electrophoretic transfer was completed under constant 
amperage of 300 mA for 2 h on ice. 
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A 3% blotting-grade blocker (Bio-Rad) solution was prepared in TBS (3% 
milk) and the membrane was blocked for 1 h at room temperature with moderate 
agitation. The blot was cut in half with each side containing a full set of SEMA3F 
dilutions. 1:1000 dilutions of 9E10 mouse anti-c-myc antibody (Santa Cruz 
Biotechnology) and rabbit anti-SEMA3F antibody were prepared in a 0.01% 
Tween 20 (Sigma-Aldrich) in TBS solution (TBST). Each half of the blot was 
incubated with either the mouse anti-c-myc or the rabbit anti-SEMA3F for 2 h at 
room temperature with moderate agitation. 
Blots were washed briefly with TBST and then washed an additional three 
times with TBST at room temperature with gentle agitation for 10 min each. 
1:3000 dilutions of NA931V HRP-linked sheep anti-mouse IgG (GE Healthcare) 
and NA934V HRP-linked donkey anti-rabbit IgG (GE Healthcare) were prepared 
in TBST. Blots were incubated with the appropriate secondary antibody dilution 
at room temperature with gentle agitation. After 1 h, blots were washed briefly 
with TBST and then washed three times with TBST under gentle agitation for 
10 min each. 
Western Lightning Plus enhanced chemiluminescent substrate (ECL, 
Perkin Elmer) was prepared by combining 1 ml each of the luminol reagent and 
oxidizing reagent. ECL solution was incubated with the nitrocellulose membrane 
for 5 min. HyBlot CL autoradiography film (Denville Scientific) was exposed and 
developed to visualize probed proteins. 
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All subsequent Western blots were transferred and developed using these 
parameters unless otherwise specified. 
SM/SEMA3F Expression of SEMA3F 
The conditioned media of SM/SEMA3F cells were assayed for the presence of 
SEMA3F. Two SM/SEMA3F clones, C3 and D1, were plated at 106 cells in a 10 cm 
tissue culture plate. When cells reached 70% confluence, plates were washed with 
10 ml serum-free MEM before adding 5 ml serum-free MEM to each plate. Cells 
were replaced in the incubator and conditioned media was collected after 24 h. 
Media was spun down at 1000 rpm for 5 min and supernatants were collected. 
For each sample, 30 μl of conditioned media and 6 μl 6x reducing sample 
buffer were combined and boiled for 10 min before loading onto a SDS-PAGE gel. 
Serum-free MEM with reducing sample buffer was loaded as a negative control 
and 300 ng SEMA3F was diluted in serum-free MEM with reducing sample 
buffer as a positive control. This and all subsequently described SDS-PAGE gels 
were run with Kaleidoscope Precision Plus Protein molecular weight markers 
(Bio-Rad). 
Gels were transferred by Western blot and probed with anti-SEMA3F 
antibody. 
Furin inhibition of SM/SEMA3F cells 
The effect of two furin inhibitors on the in vitro cleavage of SEMA3F by 
SM/SEMA3F clone C3 was assayed. Furin inhibitor I (RVKR-CMK, Calbiochem), 
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decanoyl-arginine-valine-lysine-arginine-chloromethylketone, is an irreversible 
competitive inhibitor of furin and other proprotein convertases. Furin inhibitor II 
(H6, Calbiochem), hexa-D-arginine, is a reversible competitive inhibitor of furin 
and other proprotein convertases. SM/SEMA3F cells were seeded into a 6-well 
plate at 105 cells/well and grown to 50% confluence. Wells were briefly washed 
with 1 ml serum-free MEM. 1 ml serum-free MEM was added to each well. Two 
wells were left untreated as controls and each of the other four were treated with 
one of 10 μM RVKR-CMK, 100 μM RVKR-CMK, 10 μM H6 or 100 μM H6. 
Cells were incubated for an additional 20 h before collecting conditioned 
media. Conditioned media was spun down at 1000 rpm for 5 min to remove cells 
from suspension and the supernatant was collected. 30 μl of conditioned media 
from each well was collected and analyzed by SDS page and Western blot using a 
rabbit anti-SEMA3F antibody. 
Thermal stability of SEMA3F in various buffers 
The stability of SEMA3F at 37 ℃ in phosphate-buffered saline (PBS, Gibco Life 
Technologies), radioimmunoprecipitation assay buffer (RIPA, Boston 
Bioproducts), Hank's balanced salt solution (HBSS, Mediatech Cellgro) and 0.9% 
NaCl saline (Hospira) was assessed. 
200 ng of SEMA3F samples were diluted in 20 μl PBS, RIPA, HBSS and 
saline, then incubated at 37 ℃ 10% CO2 for 24 h. A dilution of SEMA3F in PBS 
was stored at 4 ℃ for 24 h to serve as a positive control. 4 μl of 6x reducing 
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sample buffer was added to each sample at 24 h and the samples were boiled 
10 min. Samples were loaded into a 15-well 1.5 mm SDS-PAGE gel and run at 
175 V for 1 h. Separated proteins were transferred by Western blot to a 
nitrocellulose membrane and blocked for 30 min at room temperature. Blot was 
blocked 30 min at room temperature and incubated overnight at 4 ℃ with 1:1000 
rabbit anti-c-myc diluted in 3% milk. 
Furin activity assessed by fluorogenic assay 
Recombinant human furin (rhFurin) was purchased from R&D Systems and its 
protease activity was assessed using the fluorogenic substrate pERTKR-AMC 
(R&D Systems). Assay buffer was prepared as a 25 mM Trizma (Sigma-Aldrich), 
1 mM CaCl2 (Sigma-Aldrich), 0.5% (w/v) Brij35 (Biomeda) solution. rhFurin was 
diluted to 4 μg/ml and pERTKR-AMC was diluted to 100 μM in assay buffer. 
Samples were loaded into a 96-well black, clear-bottomed plate (Corning). 
Experimental wells were prepared in triplicate by the addition of 50 μl rhFurin 
dilution to each well. Substrate blanks were prepared in triplicate by adding 50 μl 
assay buffer to each well. The reaction was started by the addition of 50 μl 
substrate to each well. Plate was read 8 times over 10 min using a Wallac 
Victor3V 1420 Multilabel Plate Counter (Perkin Elmer). Excitation and emission 
wavelengths were 355 nm and 460 nm, respectively. The optimal excitation 
wavelength of 7-amino-4-methylcoumarin (AMC) is 380 nm. 
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Effect of duration on furin digest of SEMA3F 
Purified SEMA3F was digested with rhFurin over various durations in order to 
characterize the kinetics of SEMA3F cleavage by furin. 300 ng SEMA3F and 
10 ng rhFurin were diluted in 30 μl PBS. 300 ng SEMA3F was added to each 
experimental sample and all samples were incubated 5 h at 37 ℃. Furin was 
withheld from one SEMA3F sample and three other samples were digested with 
10 ng rhFurin at 0, 2 and 4 h, resulting in furin digest durations of 0, 1, 3 and 5 h. 
Two negative controls, ddH2O and PBS, were also included. 
At the 5 h time point, reducing sample buffer was added to each digest 
vessel and samples were boiled for 10 min. Samples were analyzed by SDS-PAGE 
and Western blot using mouse anti-c-myc. 
An additional rhFurin digest examining the effect of digest time on 
SEMA3F cleavage was performed with longer digest times. This digest was set up 
in the same manner as the previous assay but considered 8, 16 and 24 h digest 
times. All samples were incubated at 37 ℃ for 24 h with one exception. Two 
positive controls were used: SEMA3F incubated at 37 ℃ and SEMA3F incubated 
at 4 ℃ for 24 h. BS and 10 ng furin diluted in PBS were used as negative controls. 
Effect of furin quantity on furin digest of SEMA3F 
The effect of furin quantity on the cleavage of SEMA3F was assayed using 
purified protein. 300 ng rhFurin was incubated at 37 ℃ for 22 h with 0, 10, 20, 
30, 40 and 100 ng rhFurin. 300 ng SEMA3F incubated 22 h at 4 ℃ served as a 
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positive control. PBS and 10 ng rhFurin diluted in PBS served as negative 
controls. 
A prolonged digest series was also performed investigating the digest of 
300 ng SEMA3F with 10, 30 and 50 ng rhFurin over a 90 h incubation period. 
Cleavage of SEMA3F assessed in vitro by transfection 
Furin-deficient RPE.40 and furin-complemented 40.fur cells were transfected 
with SEMA3F to investigate the ability of furin to cleave SEMA3F in vitro. 
pSecTag2A SEMA3F was modified to include an N-terminal HA tag (pSecTag2A 
HA-SEMA3F) by a previous lab member, Akio Shimizu. Transfection with this 
plasmid was performed using the Fugene 6 reagent (Roche). Cells were seeded in 
a six-well plate at a density of 1–1.5 × 105 cells/well and were transfected at 50-
75% confluence. 
For each well, the transfection cocktail was prepared as follows. 1.5 μl 
Fugene was added directly to 50 μl of complete DMEM/F12 and allowed to 
incubate for five minutes. 0.5 μg pSecTag2A HA-SEMA3F plasmid was added 
directly to the Fugene/medium solution and allowed to incubate an additional 15 
minutes. 
Media in each well was replaced with 1 ml complete media and the 
transfection cocktail was added to the well. Cells were incubated 20 h at 37 ℃, 5% 
CO2. Wells were washed with 0.5 ml serum-free media and then 0.5 ml serum-
free DMEM/F12. Cells were incubated for an additional 48 h before collecting 
conditioned media. Conditioned media was spun at 1000 rpm for 5 min to pellet 
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cells and the supernatant was collected. 30 μl of each conditioned media sample 
was analyzed by SDS-PAGE and Western blot using rabbit anti-SEMA3F 
antibody. 
Assessment of RNAi transfection efficiency of SM/SEMA3F cells 
RNAi knockdown of NRP2 in SM/SEMA3F cells 
Stably transfected cells often have poor transfection efficiency for additional 
plasmids or RNAi. The ability of siRNA to silence NRP2 in SM/SEMA3F cells was 
assessed in vitro. SiGENOME siRNA to NRP2 (siNRP2) was purchased as a 
20 μM stock from Dharmacon. SM/SEMA3F cells were seeded in a 6-well plate at 
a density of 105 cells/well. Cells were cultured to 70% confluence and media was 
replaced with 1.25 ml fresh complete MEM. Cells were divided into three 
treatment groups: control, 20 nM siNRP2 and 60 nM siNRP2 treatment groups. 
For the 20 nM siNRP2 treatment group, 3 μl siLentFect Lipid reagent 
(Bio-Rad) and 122 μl Opti-MEM (Gibco Life Technologies) for each well were 
combined in a microcentrifuge tube and incubated 5 min at room temperature. 
Concurrently, in another microcentrifuge tube, 1.5 μl siNRP2 was combined with 
123.5 μl Opti-MEM for each well and incubated for 5 min. Both solutions were 
combined and incubated for 15 min. Combined solution (250 μl) was added to 
each well, gently swirling to distribute transfection cocktail. SM/SEMA3F cells 
were returned to the tissue culture incubator for 4 h, after which media were 
replaced with complete MEM. 
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The 60 nM siNRP2 treatment group was prepared as above, except that 
the amount of 20 μM siNRP2 was increased to 4.5 μl/well and the Opti-MEM was 
decreased correspondingly. Untreated control groups received 250 μl Opti-MEM 
in addition to the 1.25 ml MEM per well. 
Collection of cell lysates 
Cell lysates were harvested 72 h post-transfection. Lysate buffer was prepared by 
dissolving one CompleteMini protease inhibitor tablet (Roche) in 10 ml RIPA. 
SM/SEMA3F cells were placed on ice and washed twice with PBS. 50 μl lysate 
buffer was added to each well and allowed to incubate 15 min. A 1.8 cm cell 
scraper (Corning) was used to completely suspend cells in the lysate buffer and 
plate was incubated for an additional 15 min on ice. Lysate solutions were 
transferred to microcentrifuge tubes and sonicated to ensure complete cell lysis. 
Lysates were spun down at 14,000 rpm for 10 minutes to pellet cell debris and 
supernatants were collected. 
DC Protein Assay 
Total protein concentration of cell lysates was measured using a DC Protein 
Assay Kit (Bio-Rad) in a flat-bottomed 96-well plate. 5 μl of sample was 
transferred into each well. Lysate samples were measured in duplicate wells. 
Standard dilutions of Bovine Serum Albumin (BSA) were prepared covering a 
range from 3 mg/ml BSA serially diluted 1:3 to a final concentration of 
0.53 mg/ml BSA. Standard samples were measured in triplicate wells. 
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Because cell lysates were prepared in RIPA, which contains detergent, a 
2% solution of Reagent S was prepared in Reagent A, resulting in Reagent A+S. 
25 μl of Reagent A+S was added to each well, followed by 200 μl Reagent B. The 
plate was incubated for 15 minutes at room temperature and absorbance was 
read at 650 nm. A linear best fit curve was plotted against the standard dilutions 
and used to determine the total amount of protein in the experimental samples. 
NRP2 knockdown visualization by Western blot 
Lysates were diluted to the same total protein concentration using lysate buffer. 
30 μl of each lysate was combined with 6 μl 6x reducing sample buffer and boiled 
for 10 min. Samples were analyzed by SDS-PAGE and Western blot. Membrane 
was blocked 30 min and probed with a 1:1000 dilution C-9 mouse anti-NRP2 
(Santa Cruz Biotechnology) in 3% milk overnight at 4 ℃. 
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RESULTS 
SEMA3F limit of detection by anti-c-myc and anti-SEMA3F antibodies 
At primary antibody dilutions of 1:1000 and secondary antibody dilutions of 
1:3000, mouse anti-c-myc and rabbit anti-SEMA3F had a lower limit of detection 
of 200 ng (Figure 5) and below 100 ng (Figure 6), respectively. 
 
Figure 5: Visualization of SEMA3F with mouse anti-c-myc antibody. 
100 ng SEMA3F is not visible and 200 ng SEMA3F appears much lighter 
than the 400 and 600 ng SEMA3F samples when labeled with anti-c-myc. 
For each of the 200, 400 and 600 ng lanes, bands were seen at roughly 95, 
130 and 180 kD. Film was exposed 60 s before developing. 
In addition to the primary expected band at 95 kD, anti-c-myc also labeled bands 
at molecular weights of ~180 kD and ~130 kD. It is possible that these 
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correspond to homodimeric p95:p95 species and heterodimeric p95:p35 species, 
respectively, suggesting that intermolecular disulfide bonds were not reduced 
and cleaved. Subsequent SDS-PAGE gels rarely show these bands, which is 
attributed to prolonged sample boiling time in these assays before gels were 
loaded. 
 
Figure 6: Visualization of SEMA3F with rabbit anti-SEMA3F 
antibody. Anti-SEMA3F-labeled bands can be seen in each of the 100, 
200, 400 and 600 ng SEMA3F lanes. Three primary bands were observed 
in all four lanes with approximate molecular weights of 67, 95 and 
180 kD. 400 and 600 ng SEMA3F lanes show additional bands at low 
molecular weights and one at ~130 kD. Film was exposed 30 s before 
developing. 
The observed anti-SEMA3F-labeled bands at sizes 67, 95 and 130 and 180 kD are 
thought to respectively correspond to the cleaved p65 isoform, p95, p95:p35 
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heterodimer and p95:p95 homodimer. Lower molecular weight bands may 
represent additional cleavage products or, more likely, non-specific binding of 
anti-SEMA3F or secondary antibodies. 
SEMA3F is partially cleaved in SM/SEMA3F conditioned medium 
SEMA3F was detectable in the unconcentrated 24 h conditioned media collected 
from SM/SEMA3F clones C3 and D1 (Figure 7). 
 
Figure 7: SEMA3F is detectable in the concentrated media of 
SM/SEMA3F cells. Film fragments shown here were both from the same 
blot. Intermediate lanes contained conditioned media from other cell types 
(data not shown) and were removed for clarity. One positive and two 
negative controls consisting of purified SEMA3F (+), ddH2O (-) and 
serum-free MEM (-) were included. Proteins were labeled with anti-
SEMA3F antibodies and film was exposed for 3 min. 
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The molecular weight of the predominant bands found in the conditioned media 
were approximately 60 and 70 kD, which are thought to represent alternative 
glycosylation of the N-terminally cleaved p65 fragment of SEMA3F. A very faint 
band at 95 kD is visible in the D1 lane and is thought to represent a very low level 
of p95 SEMA3F. These results indicate that SM/SEMA3F cells either 
proteolytically process SEMA3F intracellularly or excrete proteases that are 
capable of cleaving SEMA3F. 
Furin inhibitors can prevent SEMA3F cleavage in vitro 
On the basis of the previous assay, SM/SEMA3F clone C3 was cultured with two 
different furin inhibitors, RVKR-CMK and H6, in order to assess the ability of 
these inhibitors to restore the expected 95 kD SEMA3F band. Both RVKR-CMK 
and H6 are able to substantially inhibit the cleavage of SEMA3F, as demonstrated 
by shift in molecular weight from 65 kD to 95 kD between control and 
experimental lanes (Figure 8). 
RVKR-CMK may inhibit SEMA3F cleavage slightly better than did H6. 
Interestingly, for both RVKR-CMK and H6, a significant difference in inhibition 
was not observed between the 10 μM and 100 μM levels. 
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Figure 8: Furin inhibitors reduce cleavage of SEMA3F in vitro. 
Unconcentrated 20 h conditioned media were collected from 
SM/SEMA3F cells treated with RVKR-CMK and H6 at two different 
concentrations. A mixture of p65 and p95 SEMA3F cleavage isoforms can 
be seen in the conditioned media of untreated control cells. Conditioned 
media from RVKR-CMK and H6-treated SM/SEMA3F cells primarily 
contain the p95 isoform. Serum-free MEM was used as a negative control 
and two different batches of purified SEMA3F were used as a positive 
control. 180 kD band in control lanes are attributed to SEMA3F p95:p95 
homodimers. Blot was labeled using anti-SEMA3F antibody and film was 
exposed for 3 min. 
SEMA3F is thermally stable in several buffers 
SEMA3F was incubated in RIPA, HBSS, 0.9% saline and PBS for 24 h at 37 ℃. 
SEMA3F suspended in PBS and stored at 4 ℃ was used as a positive control. 
SEMA3F does not appear to degrade significantly when incubated at 37 ℃ in 
RIPA, HBSS, saline or PBS for 24 h, although there were small variations in the 
quantity of p65 and smaller bands. Notably, incubation with RIPA induced a 
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band at roughly 180 kD. This is tentatively suggested to be caused by increased 
aggregation of SEMA3F molecules due to the high detergent levels in RIPA. 
 
Figure 9: SEMA3F is thermally stable for up to 24 h in 37 ℃ RIPA, 
HBSS, saline and PBS. Lanes corresponding to incubation in HBSS, 
saline and PBS look identical to the control lane. Incubation of SEMA3F 
in RIPA did not display significant changes in p95 levels, but did induce a 
180 kD band. Each buffer was loaded separately as a negative control. 
Blot was labeled with anti-c-myc antibody and film was exposed for 10 s. 
rhFurin actively cleaves pERTKR-AMC 
Cleavage of the fluorogenic substrate pERTKR-AMC was used in order to assess 
the proteolytic activity of rhFurin. Substrate alone maintained a relatively 
constant level of fluorescence, whereas the addition of rhFurin induced an 
increasing level of fluorescence over time. This suggests that rhFurin is able to 
actively cleave pERTKR and release the fluorogenic molecule AMC. 
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Figure 10: Furin digest of fluorogenic pERTKR-AMC. Over a time 
period of 10 minutes, the fluorescence’s of an rhFurin/pERTKR-AMC 
solution was observed to increase linearly, suggesting that rhFurin was 
processing pERTKR-AMC and releasing the fluorogenic compound 
AMC. The fluorescence of pERTKR-AMC without rhFurin remained 
constant. Standard deviation for each time point (n=3) are shown as error 
bars. 
SEMA3F does not exhibit significant cleavage by low rhFurin levels 
SEMA3F did not appear to be significantly processed when incubated with 10 ng 
rhFurin up to 5 h (Figure 11). Control and digest lanes appear largely identical for 
the intensity of 95 and 65 kD bands. The 1 h digest may be an exception, with a 
slightly darker 65 kD band than the other lanes. However, higher p65 levels at 1 h 
digest than at 3 and 5 h digests is inconsistent with rhFurin-mediated cleavage. 
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Figure 11: Cleavage of SEMA3F is not evident up to five hours. At the 
95 kD size, there was no change between the SEMA3F positive control, 
which was incubated at 37 ℃ 5 h without furin, and the rhFurin-incubated 
samples. The 1 h incubation may have higher levels of the 65 kD isoform, 
but this elevation was not seen at 3 and 5 h. Blot was labeled with anti-
c-myc antibody and film was exposed for 3 min. 
In order to determine if cleavage might be observed with longer digest times, 
SEMA3F was incubated with furin for up to 24 h (Figure 12). Again, no cleavage 
was observed. 
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Figure 12: Cleavage of SEMA3F is not evident after incubating with 
10 ng rhFurin up to 24 h. No change in band intensity was observed 
between control samples and experimental samples incubated with 
rhFurin. Blot was labeled with anti-c-myc antibodies and film was 
exposed 30 s. 
Cleavage of purified SEMA3F is still not evident at high rhFurin levels 
In order to identify if SEMA3F cleavage was not observed due to insufficient 
rhFurin levels, up to 100 ng rhFurin was incubated with 300 ng SEMA3F at 37 ℃ 
for 22 h (Figure 13). Although the banding pattern in some lanes appears slightly 
different than that in the 4 ℃-incubated sample or the 0 ng rhFurin sample, there 
is no discernable pattern between banding pattern and rhFurin levels. Even at a 
3:1 ratio of SEMA3F to rhFurin, no cleavage was observed. 
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Figure 13: SEMA3F is not cleaved in the presence of furin up to a 
ratio of 3:1 SEMA3F:rhFurin. Bands corresponding to 95 kD and 65 kD 
SEMA3F isoforms were visible in all SEMA3F lanes. No relationship 
between rhFurin level and isoform levels was observed. Blot was labeled 
with anti-SEMA3F antibody and film was exposed for 15 s. 
In order to test if cleavage might have been observed with even longer digest 
times, SEMA3F was incubated with up to 50 ng rhFurin for 90 h (Figure 14). 
Even at these furin levels and digest durations, SEMA3F cleavage was not 
observed. It appears that the 10 ng rhFurin lane has a relatively higher level of 
the p65 SEMA3F isoform as compared to positive controls. However, the level of 
p65 SEMA3F in this sample is also higher than that in samples with still higher 
rhFurin levels. Therefore, no discernable relationship between rhFurin levels and 
SEMA3F cleavage was observed. 
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Figure 14: SEMA3F is not cleaved by rhFurin over a 90 h period. Two 
bands can be observed between the 75 and 100 kD molecular weight 
markers and are thought to represent alternative glycosylation of 
SEMA3F. No discernable difference between the higher molecular weight 
glycosylation was observed between SEMA3F controls and rhFurin-
incubated samples. Lower molecular weight glycosylation appeared to be 
reduced in samples with higher levels of rhFurin, but no corresponding 
increase in a lower molecular weight isoform was observed, as would be 
expected if cleavage had occurred. The 10 ng rhFurin digest appears to 
have higher levels of the 65 kD SEMA3F isoform, but no trend between 
rhFurin and p65 levels were observed. Faint 25 kD bands are thought to 
represent non-specific binding of the anti-HA antibody. Blot was labeled 
with anti-HA antibody and film was exposed for 30 min. 
All digests included in this paper were conducted in a reaction solution whose 
primary component was PBS. In addition, digests were performed in HBSS and 
serum-free MEM (data not shown) in order to  account for the possibility that 
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rhFurin cofactors might not have been present. Digest results appear very similar 
to those included here. 
SEMA3F Transfection of RPE.40 and 40.fur cells is inconclusive 
Furin-deficient RPE.40 cells and furin-transfected 40.fur cells were transfected 
with pSecTag2A HA-SEMA3F in order to assess the ability of furin to cleave 
SEMA3F in vitro (Figure 15 and Figure 16). 
 
Figure 15: RPE.40 cells did not appear to secrete SEMA3F 48 h post-
transfection. Conditioned media was collected from biological replicates 
of untransfected (∅) cells, SEMA3F-transfected cells and SEMA3F-
transfected cells cultured with RVKR-CMK. Faint bands were observed at 
60 kD, but did not differ in level between groups. Blot was labeled with 
anti-SEMA3F and film was exposed for 30 min. 
Conditioned media were collected from three groups: untransfected cells, 
SEMA3F-transfected cells and SEMA3F-transfected cells cultured in the presence 
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of 10 μM RVKR-CMK. Cells were cultured 48 h post-transfection before 
collecting conditioned media. 
Both RPE.40 and 40.fur cells appear to excrete low-levels of a 60 kD 
protein. However, no difference was observed in the levels of this protein 
between control groups and the two experimental groups. This suggests that 
either RPE.40 and 40.fur cells transfected with SEMA3F do not excrete the 
expressed protein or that the transfection was unsuccessful. 
 
Figure 16: 40.fur cells did not appear to secrete SEMA3F 48 h post-
transfection. Conditioned media was collected from biological replicates 
of untransfected (∅) cells, SEMA3F-transfected cells and SEMA3F-
transfected cells cultured with RVKR-CMK. Faint bands were observed at 
60 kD, but did not differ in level between groups. Blot was labeled with 
anti-SEMA3F and film was exposed for 30 min. 
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siNRP2 shows tentative knockdown of NRP2 in SM/SEMA3F 
In order to assess the ability of RNAi to successfully downregulate gene 
expression in SM/SEMA3F cells, siRNA was used to knockdown NRP2 levels 
(Figure 17). 
 
Figure 17: Knockdown of NRP2 in SM/SEMA3F cells by siNRP2 was 
tentatively successful. A row of bands at ~120 kD (indicated by arrow), 
potentially corresponding to NRP2, was found to decrease in intensity 
when SM/SEMA3F cells were treated with siNRP2. However, this blot 
shows a high level of non-specific antibody binding interactions. Blot was 
labeled with an anti-NRP2 antibody and film was exposed for 10 min 
The molecular weight of NRP2 is approximately 120 kD, which corresponds to a 
row of bands that reduce in intensity following treatment of SM/SEMA3F cells 
with siNRP2. However, this blot displayed a high level of non-specific anti-NRP2 
antibody binding, so it is difficult to confirm that this row of bands truly 
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corresponds to NRP2. Promisingly, the non-specific banding patterns appear 
identical between lanes, suggesting that cell lysates were loaded at equal 
concentrations. 
The most intensely labeled bands were located at a molecular weight of 
approximately 55 kD. It is unknown to what protein this band may correspond. 
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DISCUSSION 
This series of experiments has shown that rhFurin is not capable of directly 
cleaving SEMA3F within the synthetic digest environment. Using the anti-
SEMA3F antibody previously raised in rabbits, as low as 100 ng SEMA3F could 
be detected by Western blot. In vitro, the change in observed molecular weight 
from predominantly 65 kD to predominantly 95 kD SEMA3F in SM/SEMA3F 
cells following the administration of RVKR-CMK or H6 is striking. However, 
these two inhibitors have been shown to interact with PCSK other than furin 
(PCSK3). RVKR-CMK is able to inhibit PCSK1-7 and H6 has been shown to 
inhibit at least PCSK1 and PCSK6 (Cameron et al., 2000; Tian & Jianhua, 2010). 
Therefore, the observed molecular weight shift in these cells primarily 
demonstrates that SEMA3F cleavage is PCSK mediated. Interestingly, H6 has 
been shown to upregulate PCSK2 activity, suggesting that PCSK2 is most likely 
not involved in the processing of SEMA3F. 
Under synthetic conditions, even with SEMA3F:rhFurin ratios 
approaching 3:1 and digest durations of up to 90 h, no evidence was found to 
support furin-mediated cleavage of SEMA3F in the context of purified protein 
interactions. We have confirmed that the rhFurin used in these experiments was 
able to cleave the fluorogenic substrate pERTKR-AMC and therefore do not 
believe that activity of the furin used is in question. Furin does rely on a calcium 
cofactor that is absent from PBS, which was used as a diluent for SEMA3F and 
rhFurin in these digests. However, because rhFurin is supplied with high levels of 
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calcium, it is not thought that this was related to the observed absence of 
cleavage. Additional digests were also conducted in a variety of buffers, including 
serum-free MEM, which is supplemented with calcium salts. Data from these 
digests are not shown, but the results were similar, again suggesting that any 
potential cleavage was not calcium-limited. Another possibility is that furin 
requires a biological cofactor in order to cleave SEMA3F. As SEMA3F has already 
been demonstrated to be cleaved in the conditioned media of SM/SEMA3F cells, 
one option to investigate this possibility might be to collect SM/SEMA3F 
conditioned media and supplement it with purified SEMA3F and varying levels of 
rhFurin. It is hypothesized that secreted proteases in the conditioned media 
could cause SEMA3F cleavage, so an additional assay comparing different 
incubation durations of SEMA3F in SM/SEMA3F conditioned media should also 
be performed. 
A weakness in this study is the absence of a good positive control for the 
rhFurin digest of SEMA3F. Furin is part of the constitutive secretory pathway 
and has been implicated in the proteolytic maturation and/or inactivation of 
many biological enzymes, hormones and peptides, such as the transforming 
growth factor β (TGF-β) family. TGF-β1 has important roles in early embryonic 
development and arteriogenesis. When co-transfected with furin in the furin-
deficient human LoVo cell line, the ~48 kD TGF-β1 was seen to be cleaved into 
~33 and ~14.5 kD fragments (Dubois et al., 2001; Thomas, 2002). Another 
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possibility is VEGF-C, which when cleaved by furin, PCSK5 or PCSK7 exhibits a 
molecular weight shift from 59 to 29 kD (Siegfried et al., 2003). 
Therapeutic application of SEMA3F is expected to benefit from increased 
biological half-life, one component of which is thermal stability at physiological 
temperatures. Although this study only specifically assessed the thermal stability 
of SEMA3F for periods up to 24 h, SEMA3F levels also remained stable over a 
90 h incubation period with rhFurin at 37 ℃. In another set of experiments 
conducted by Matthew Migliozzi, Meetu Seth and Diane Bielenberg, two week 
administration of purified SEMA3F was achieved using a slow release osmotic 
pump co-implanted into mice with B16F10 mouse melanoma cells over a period 
of 27 days (unpublished data, 2013). When the osmotic pumps were implanted 
four days prior to tumor cells injections, but not when they were implanted nine 
days after, the resulting tumors exhibited decreased tumor volumes. Taken 
together, these data suggest that SEMA3F may be able to retain biological activity 
over durations of up to two weeks when protected from cleaveage. If so, delayed 
release delivery modalities for SEMA3F may be able to reduce the burden of 
receiving daily cancer treatment. It is important to note that none of these 
experiments are able to directly address the change in SEMA3F activity over 
prolonged exposures to 37 ℃ temperatures. In order to do so, collapse or 
migration assays utilizing SEMA3F subjected to varying 37 ℃ incubation times 
would need to be performed. 
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In an attempt to confirm the results of our purified protein digests in vitro, 
we examined the transfection of furin-deficient and furin-complemented CHO-K1 
strains, respectively RPE.40 and 40.fur, with SEMA3F plasmid. At this point in 
time, the data suggest that the transfection of these cells lines was either not 
successful or that SEMA3F was not secreted into the assayed conditioned media, 
but was instead sequestered by the CHO-K1 cells. As CHO-K1 cells are widely 
used for protein synthesis and protein expression studies because they are easily 
transfected and have highly active secretory pathways, it seems unlikely that they 
are sequestering the SEMA3F. 
In the transfection of CHO-K1 strains RPE.40 and 40.fur, 0.5 μg plasmid 
DNA per well in a 6-well plate was utilized. It has been found previously that this 
level is sufficient for high-efficiency transfection of HEK293 cells (Bielenberg et 
al., 2008). However, in transfecting RPE.40 cells with mouse furin to produce 
40.fur, Moehring et al. (1993) used 20 μg of plasmid DNA per 5 × 105 cells in a 
calcium phosphate-based transfection method (Chen & Okayama, 1987). As each 
of the wells in this study was seeded with 1–1.5 × 105 cells, this represents at least 
a four-fold increase over the levels of plasmid DNA used in these transfections. 
Similarly, Kadlecova et al. (2012) transfected CHO-K1 cells using the Fugene 
reagent, as was done here, but utilizing 0.8 μg of plasmid DNA per well of a 12-
well plate. Accounting for the difference in surface area between wells of 6-well 
and 12-well plates, this again represents a four-fold difference in plasmid amount 
used for transfection of CHO-K1 cells. 
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Future assays will increase the amount of plasmid used to transfect these 
cells in order to increase the transfection efficiency. If the transfection was 
successful in some cells, an alternative approach may be to enrich the 
conditioned media for glycoproteins in order to increase the concentration of 
SEMA3F to levels detectable by Western blot. One method to accomplish this 
might involve the use of sepharose beads incorporating concanavalin A. 
The finding that rhFurin was unable to cleave SEMA3F in pure protein 
studies was surprising given the large body of literature that implicates furin or 
furin-like proteases in the cleavage of the semaphorin family. However, these 
studies primarily rely on the usage of non-specific furin inhibitors, especially 
RVKR-CMK, that are unable to selectively inhibit specific PCSK (Adams et al., 
1997; Cameron et al., 2000; Christensen et al., 2005; Parker et al., 2010; Tian & 
Jianhua, 2010; Varshavsky et al., 2008; Zhong et al., 1999). 
In experiments involving a fusion protein of human growth hormone and 
the C-terminal portion of SEMA3F (residues 605-785), Parker et al. (2010) 
reported that the furin-deficient CHO mutant FD11 was unable to cleave this 
fusion protein, whereas cleavage was observed in a furin-overexpressing CHO cell 
line. As they were primarily interested in the p100 to p95 cleavage, their fusion 
protein incorporated only residues C-terminal to the predicted p65 cleavage site 
KRRSRR. If furin does cleave the p95 cleavage site and not the p65 cleavage site, 
this may suggest a mechanism for the specific activation and inhibition of 
SEMA3F by proteolytic processing. 
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Discovery of a mechanism by which SEMA3 are selectively cleaved either 
to p95 or p65 forms would have profound implications. As previously mentioned, 
cleavage of SEMA3 have isoform-specific effects. Cleavage at the p65 site 
inactivates the repelling signals SEMA3A-B and converts the repelling signal 
SEMA3E to a prometastatic phenotype (Adams et al., 1997; Christensen et al., 
2005; Klostermann et al., 1998; Varshavsky et al., 2008). As tumors typically 
upregulate PCSK activity, it follows that cleavage of the SEMA3 should result in 
tumor-favorable conditions, suggesting a trend wherein the p95 isoform is either 
more tumor-inhibiting or less tumor-enhancing than the corresponding p65 
isoform. However, this trend may not be generalizable. Esselens et al. (2010) 
have suggested that SEMA3C which has been processed at the p95 site by the 
metalloproteinase ADAMTS1 is in fact prometastatic. 
The activity of SEMA3F fragments has not been well characterized. Using 
a recombinant construct corresponding to the C-terminal end of the p30 
fragment liberated from the cleavage of p95 to p65 SEMA3F, Guo et al. (2013) 
have suggested that the p30 fragment may be able to inhibit the interaction of 
VEGF with NRP1. If so, it is possible that this could present an additional 
therapeutic effect of administered full-length SEMA3F even after initial cleavage. 
It is also interesting that the p30 fragment of SEMA3F may interact with NRP1 
when SEMA3F typically interacts with NRP2. However, SEMA3G displays similar 
activity, binding only NRP2 when full-length but both NRP1 and NRP2 post-
processing (Kutschera et al., 2011). 
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Given the diverse nature of the bioactive SEMA3 cleavage fragments, more 
experiments will need to be conducted in order to specifically determine the role 
of p65 SEMA3F. If the protease responsible for SEMA3F cleavage is identified, 
one option to generate p65 SEMA3F may be to simply digest purified SEMA3F 
and use a size-exclusion filter to isolate the p65 isoform. One concern with this 
method is that the yield might be very low. Another option is to create an 
expression vector corresponding to p65 SEMA3F based on cleavage at the p65 
putative cleavage site. In order to purify such a protein, it might be prudent to 
shift the His-tag from its current C-terminal position in the SEMA3F construct 
used for these studies to the N-terminal position in order not to interfere with 
any interactions occurring at the “cleaved” C-terminal end. To our knowledge, 
there have been no reports at this time of SEMA3F inducing a protumorigenic or 
prometastatic effect. As such, we do hypothesize that the p65 SEMA3F isoform at 
the very least does not encourage tumor growth or metastasis and may simply be 
inactive. 
In addition to studying the cleavage of SEMA3F in RPE.40 and 40.fur 
cells, another approach would be to use siRNA as a method to downregulate 
specific proprotein convertases. This study suggests that SM/SEMA3F cells may 
be amenable to the use of siRNA. When SM/SEMA3F cells were exposed to 
siNRP2, there was a corresponding decrease in the levels of a ~120 kD protein 
that may correspond to NRP2. Follow-up assays are currently being conducted to 
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confirm this finding. In addition, the specificity of the NRP2 knockdown will be 
assessed by stripping and reprobing the blot with anti-NRP1 antibodies. 
Data from the RVKR-CMK and H6 inhibition of SM/SEMA3F cells suggest 
that all PCSK except PCSK2 may be potential SEMA3 protease candidates for 
silencing by siRNA. Siegfried et al. (2003) have reported that VEGF-C, a 
competitive ligand for SEMA3F receptor NRP2, is cleaved and activated by furin, 
PCSK5 and PCSK7. Upon cleavage of proVEGF-C, mature VEGF-C is able to bind 
VEGFR2 and VEGFR3, activating both lymphangiogenesis and angiogenesis. 
Additional binding of NRP2 by mature VEGF-C is able to enhance the activation 
of VEGFR2 and VEGFR3 (Neufeld & Kessler, 2008; Xu et al., 2010). 
Interestingly, proVEGF-C is also able to bind VEGFR2 and VEGFR3, but it 
results in no autophosporylation of VEGFR2 and only weak phosphorylation of 
VEGFR3, demonstrating that proVEGF-C acts as an inhibitor of VEGF-C function 
(Joukov et al., 1997). The VEGF-C/NRP2/VEGFR2-3 axis is therefore a highly 
interesting therapeutic target for the prevention of blood and lymph vessel 
ingrowth which can facilitate tumor growth and metastasis. As SEMA3F also 
binds to NRP2 and is a negative regulator of lymphangiogenesis, an attractive 
hypothesis is therefore that one of these VEGF-C-cleaving proteases may also 
cleave and inactivate SEMA3F, facilitating the switch from an antiangiogenic 
state to a proangiogenic state. 
As previously mentioned, wild-type SEMA3B is a particularly poor 
inhibitor of tumor progression because it is predominantly cleaved in the tumor 
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microenvironment. Therefore, studies investigating SEMA3B typically use a 
recombinant variant that lacks the p65 cleavage site (Varshavsky et al., 2008). 
Similarly, not all tumors respond to SEMA3F, presumably because they 
either process and inactivate SEMA3F or lack the functional receptor, such as 
MCF7 breast tumor cells (Kigel et al., 2008). Identifying the proteases 
responsible for SEMA3F cleavage would help to better target SEMA3F therapy to 
receptive tumor targets and also help clarify why some tumors are refractory to 
SEMA3F treatment, such as NCI-H1299 or GLC45 lung cancer lines (Bielenberg 
et al., 2006). Identification of proteases for SEMA3F might also enable co-
administration of SEMA3F with protease inhibitors in the future. 
As another approach, this lab has engineered a recombinant SEMA3F 
construct, SEMA3FR, with a similar mutation in the p65 cleavage site (RRSRR  
RASRA). Under the assumption that cleavage of SEMA3F to the p65 isoform 
inactivates SEMA3F, it is expected that SEMA3FR would exhibit greater 
therapeutic effect in the treatment of cancer due to its increased half-life. 
In summary, these experiments suggest that despite numerous literature 
reports of furin-like PCSK cleavage of the SEMA3 family, furin itself may not 
cleave SEMA3F. Understanding the protease-specificity of the putative cleavage 
sites in SEMA3 family members and the activity of the resulting cleavage 
fragments of SEMA3F is expected to enhance the ability of SEMA3F to be used 
therapeutically. Future approaches to the study of SEMA3F cleavage will 
incorporate purified protein digests conducted within conditioned media, 
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expression of SEMA3F in PCSK-positive and PCSK-negative cell lines and siRNA 
approaches to silencing potential PCSK candidates for the cleavage of SEMA3F. 
48 
REFERENCES 
Adams, R. H., Lohrum, M., Klostermann, A., Betz, H., & Püschel, A. W. (1997). 
The chemorepulsive activity of secreted semaphorins is regulated by furin-
dependent proteolytic processing. The EMBO Journal, 16(20), 6077–
6086. doi:10.1093/emboj/16.20.6077 
Appleton, B. A., Wu, P., Maloney, J., Yin, J., Liang, W.-C., Stawicki, S., … 
Wiesmann, C. (2007). Structural studies of neuropilin/antibody 
complexes provide insights into semaphorin and VEGF binding. The 
EMBO Journal, 26(23), 4902–4912. doi:10.1038/sj.emboj.7601906 
Bielenberg, D. R., Hida, Y., Shimizu, A., Kaipainen, A., Kreuter, M., Kim, C. C., & 
Klagsbrun, M. (2004). Semaphorin 3F, a chemorepulsant for endothelial 
cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor 
phenotype. The Journal of Clinical Investigation, 114(9), 1260–1271. 
doi:10.1172/JCI21378 
Bielenberg, D. R., & Klagsbrun, M. (2007). Targeting endothelial and tumor cells 
with semaphorins. Cancer Metastasis Reviews, 26(3-4), 421–431. 
doi:10.1007/s10555-007-9097-4 
Bielenberg, D. R., Pettaway, C. A., Takashima, S., & Klagsbrun, M. (2006). 
Neuropilins in neoplasms: expression, regulation, and function. 
Experimental Cell Research, 312(5), 584–593. 
doi:10.1016/j.yexcr.2005.11.024 
Bielenberg, D. R., Shimizu, A., & Klagsbrun, M. (2008). Semaphorin-induced 
cytoskeletal collapse and repulsion of endothelial cells. Methods in 
Enzymology, 443, 299–314. doi:10.1016/S0076-6879(08)02015-6 
Cameron, A., Appel, J., Houghten, R. A., & Lindberg, I. (2000). Polyarginines Are 
Potent Furin Inhibitors. Journal of Biological Chemistry, 275(47), 36741–
36749. 
Chen, C., & Okayama, H. (1987). High-efficiency transformation of mammalian 
cells by plasmid DNA. Molecular and Cellular Biology, 7(8), 2745–2752. 
Christensen, C., Ambartsumian, N., Gilestro, G., Thomsen, B., Comoglio, P., 
Tamagnone, L., … Lukanidin, E. (2005). Proteolytic processing converts 
the repelling signal Sema3E into an inducer of invasive growth and lung 
metastasis. Cancer Research, 65(14), 6167–6177. doi:10.1158/0008-
5472.CAN-04-4309 
49 
Dubois, C. M., Blanchette, F., Laprise, M.-H., Leduc, R., Grondin, F., & Seidah, N. 
G. (2001). Evidence that Furin Is an Authentic Transforming Growth 
Factor-?1-Converting Enzyme. The American Journal of Pathology, 
158(1), 305–316. 
Esselens, C., Malapeira, J., Colomé, N., Casal, C., Rodríguez-Manzaneque, J. C., 
Canals, F., & Arribas, J. (2010). The cleavage of semaphorin 3C induced by 
ADAMTS1 promotes cell migration. The Journal of Biological Chemistry, 
285(4), 2463–2473. doi:10.1074/jbc.M109.055129 
Gaur, P., Bielenberg, D. R., Samuel, S., Bose, D., Zhou, Y., Gray, M. J., … Ellis, L. 
M. (2009). Role of class 3 semaphorins and their receptors in tumor 
growth and angiogenesis. Clinical Cancer Research: An Official Journal of 
the American Association for Cancer Research, 15(22), 6763–6770. 
doi:10.1158/1078-0432.CCR-09-1810 
Guo, H.-F., Li, X., Parker, M. W., Waltenberger, J., Becker, P. M., & Vander Kooi, 
C. W. (2013). Mechanistic basis for the potent anti-angiogenic activity of 
semaphorin 3F. Biochemistry, 52(43), 7551–7558. doi:10.1021/bi401034q 
Joukov, V., Sorsa, T., Kumar, V., Jeltsch, M., Claesson-Welsh, L., Cao, Y., … 
Alitalo, K. (1997). Proteolytic processing regulates receptor specificity and 
activity of VEGF-C. The EMBO Journal, 16(13), 3898–3911. 
doi:10.1093/emboj/16.13.3898 
Kadlecova, Z., Rajendra, Y., Matasci, M., Hacker, D., Baldi, L., Wurm, F. M., & 
Klok, H.-A. (2012). Hyperbranched polylysine: a versatile, biodegradable 
transfection agent for the production of recombinant proteins by transient 
gene expression and the transfection of primary cells. Macromolecular 
Bioscience, 12(6), 794–804. doi:10.1002/mabi.201100519 
Kigel, B., Varshavsky, A., Kessler, O., & Neufeld, G. (2008). Successful Inhibition 
of Tumor Development by Specific Class-3 Semaphorins Is Associated 
with Expression of Appropriate Semaphorin Receptors by Tumor Cells. 
PLoS ONE, 3(9). doi:10.1371/journal.pone.0003287 
Klostermann, A., Lohrum, M., Adams, R. H., & Püschel, A. W. (1998). The 
Chemorepulsive Activity of the Axonal Guidance Signal Semaphorin D 
Requires Dimerization. Journal of Biological Chemistry, 273(13), 7326–
7331. doi:10.1074/jbc.273.13.7326 
Kutschera, S., Weber, H., Weick, A., Smet, F. D., Genove, G., Takemoto, M., … 
Augustin, H. G. (2011). Differential Endothelial Transcriptomics Identifies 
Semaphorin 3G as a Vascular Class 3 Semaphorin. Arteriosclerosis, 
50 
Thrombosis, and Vascular Biology, 31(1), 151–159. 
doi:10.1161/ATVBAHA.110.215871 
Li, L., Price, J. E., Fan, D., Zhang, R., Bucana, C. D., & Fidler, I. J. (1989). 
Correlation of Growth Capacity of Human Tumor Cells in Hard Agarose 
With Their In Vivo Proliferative Capacity at Specific Metastatic Sites. 
Journal of the National Cancer Institute, 81(18), 1406–1412. 
doi:10.1093/jnci/81.18.1406 
Miao, H.-Q., Soker, S., Feiner, L., Alonso, J. L., Raper, J. A., & Klagsbrun, M. 
(1999). Neuropilin-1 Mediates Collapsin-1/Semaphorin III Inhibition of 
Endothelial Cell Motility. The Journal of Cell Biology, 146(1), 233–242. 
Moehring, J. M., Inocencio, N. M., Robertson, B. J., & Moehring, T. J. (1993). 
Expression of mouse furin in a Chinese hamster cell resistant to 
Pseudomonas exotoxin A and viruses complements the genetic lesion. The 
Journal of Biological Chemistry, 268(4), 2590–2594. 
Neufeld, G., & Kessler, O. (2008). The semaphorins: versatile regulators of 
tumour progression and tumour angiogenesis. Nature Reviews. Cancer, 
8(8), 632–645. doi:10.1038/nrc2404 
Parker, M. W., Hellman, L. M., Xu, P., Fried, M. G., & Vander Kooi, C. W. (2010). 
Furin processing of semaphorin 3F determines its anti-angiogenic activity 
by regulating direct binding and competition for neuropilin. Biochemistry, 
49(19), 4068–4075. doi:10.1021/bi100327r 
Remacle, A. G., Shiryaev, S. A., Oh, E.-S., Cieplak, P., Srinivasan, A., Wei, G., … 
Strongin, A. Y. (2008). Substrate cleavage analysis of furin and related 
proprotein convertases. A comparative study. The Journal of Biological 
Chemistry, 283(30), 20897–20906. doi:10.1074/jbc.M803762200 
Shimizu, A., Mammoto, A., Italiano, J. E., Jr, Pravda, E., Dudley, A. C., Ingber, D. 
E., & Klagsbrun, M. (2008). ABL2/ARG tyrosine kinase mediates 
SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human 
glioma cells. The Journal of Biological Chemistry, 283(40), 27230–27238. 
doi:10.1074/jbc.M804520200 
Siegfried, G., Basak, A., Cromlish, J. A., Benjannet, S., Marcinkiewicz, J., 
Chrétien, M., … Khatib, A.-M. (2003). The secretory proprotein 
convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. 
The Journal of Clinical Investigation, 111(11), 1723–1732. 
doi:10.1172/JCI17220 
51 
Thomas, G. (2002). FURIN AT THE CUTTING EDGE: FROM PROTEIN 
TRAFFIC TO EMBRYOGENESIS AND DISEASE. Nature Reviews. 
Molecular Cell Biology, 3(10), 753–766. doi:10.1038/nrm934 
Tian, S., & Jianhua, W. (2010). Comparative study of the binding pockets of 
mammalian proprotein convertases and its implications for the design of 
specific small molecule inhibitors. International Journal of Biological 
Sciences, 6(1), 89–95. 
Unified nomenclature for the semaphorins/collapsins. Semaphorin 
Nomenclature Committee. (1999). Cell, 97(5), 551–552. 
Varshavsky, A., Kessler, O., Abramovitch, S., Kigel, B., Zaffryar, S., Akiri, G., & 
Neufeld, G. (2008). Semaphorin-3B is an angiogenesis inhibitor that is 
inactivated by furin-like pro-protein convertases. Cancer Research, 
68(17), 6922–6931. doi:10.1158/0008-5472.CAN-07-5408 
Xiang, R., Davalos, A. R., Hensel, C. H., Zhou, X.-J., Tse, C., & Naylor, S. L. 
(2002). Semaphorin 3F gene from human 3p21.3 suppresses tumor 
formation in nude mice. Cancer Research, 62(9), 2637–2643. 
Xu, Y., Yuan, L., Mak, J., Pardanaud, L., Caunt, M., Kasman, I., … Bagri, A. 
(2010). Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting 
together with VEGFR3. The Journal of Cell Biology, 188(1), 115–130. 
doi:10.1083/jcb.200903137 
Zhong, M., Munzer, J. S., Basak, A., Benjannet, S., Mowla, S. J., Decroly, E., … 
Seidah, N. G. (1999). The Prosegments of Furin and PC7 as Potent 
Inhibitors of Proprotein Convertases IN VITRO AND EX VIVO 
ASSESSMENT OF THEIR EFFICACY AND SELECTIVITY. Journal of 
Biological Chemistry, 274(48), 33913–33920. 
52 
CURRICULUM VITAE 
ERIK LI 
Address: 1642 Martha Terrace 
Rockville, MD 20852 
Birth Year:  1988 
EDUCATION 
Boston University  expected grad. May 2014 
Master of Arts in Medical Sciences  GPA 3.7  MCAT 41 
Provost's Scholarship 
University of Maryland, College Park grad. May 2010 
cum laude BS in Bioengineering, Honors and Gemstone Citations  GPA 3.7 
Banneker-Key Full Scholarship 
Outstanding Senior in Bioengineering 
Best Capstone Thesis 
EXPERIENCE 
Vascular Biology Program, Boston Children’s Hospital 2013–Present 
Graduate Student Bethesda, MD  
Investigated the cleavage of semaphorins, a family of molecules implicated in 
neuronal guidance, angiogenesis and tumor biology; mentored by Dr. Diane 
Bielenberg. 
Dr. Christopher Unger, M.D. 2011–2012 
Volunteer Technical/Medical Assistant Bethesda, MD  
Collected patient histories and vitals, recorded operative notes, took EKG 
readings, answered phone 
Branchville Volunteer Fire Department 2009–2012 
Volunteer Emergency Medical Technician College Park, MD 
Provided emergency medical care and transported patients to hospital 
Upward Bound Program, University of Maryland Summer 2011 
Tutor/Counselor, Lecturer College Park, MD 
Tutored high school students across all academic subjects, lectured 16 hours/wk 
on computing topics 
53 
Tissue Engineering and Biomaterials Lab 2008–2010 
Student Research Intern, University of Maryland College Park, MD 
Developed methodology to synthesize polymeric bilayer scaffold for hernia repair 
purposes, studied scaffold's mechanical properties, characterized hydrolytic 
degradation of scaffold. 
Publications 
EE Falco, EE Coates, E Li, JS Roth, and JP Fisher. Fabrication and 
Characterization of Porous EH Scaffolds and EH-PEG Bilayers. Journal of 
Biomedical Materials Research, Part A. 97(3):264-71. 
EE Falco, MO Wang, JA Thompson, JM Chetta, DM Yoon, EZ Li, MM 
Kulkami, S Shah, A Pandit, JS Roth, and JP Fisher. Porous EH and EH-
PEG Scaffolds as Gene Delivery Vehicles to Skeletal Muscle. 
Pharmaceutical Research. 28(6):1306-16. 
Fellowships 
ASPIRE Fellowship –  Spring 2009 
ASPIRE Fellowship – Fall 2008 
Molecular and Cellular Bioengineering Research Experiences for 
Undergraduates (REU) Fellowship – Summer 2008 
Gemstone Program, University of Maryland 2006–2010 
Lead Programmer and Webmaster, Team CHIP College Park, MD 
Developed post-stroke rehabilitation system as part of a twelve-person team 
under Dr. Pamela Abshire 
Awards 
Best Thesis 2010, Team CHIP 
High Resolution Electron Microscopy Department Summer 2005 
Student Research Intern, National Institutes of Health Bethesda, MD 
Developed three-dimensional registration and feature averaging algorithm for 
visualization of Simian Immunodeficiency Virus surface protein gp120; mentored 
by Dr. Sriram Subramaniam 
